Legal & General Group Plc Has $3.70 Million Holdings in Enovis Co. (NYSE:ENOV)

Legal & General Group Plc decreased its holdings in Enovis Co. (NYSE:ENOV) by 5.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 84,241 shares of the company’s stock after selling 5,253 shares during the quarter. Legal & General Group Plc owned 0.15% of Enovis worth $3,696,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ENOV. Vanguard Group Inc. raised its position in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company’s stock worth $240,731,000 after purchasing an additional 75,348 shares in the last quarter. DAVENPORT & Co LLC boosted its stake in Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after buying an additional 157,216 shares in the last quarter. Royce & Associates LP grew its position in Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock valued at $108,409,000 after acquiring an additional 66,891 shares during the period. River Road Asset Management LLC raised its stake in Enovis by 3.8% during the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company’s stock worth $54,339,000 after acquiring an additional 45,762 shares in the last quarter. Finally, Boston Partners lifted its holdings in shares of Enovis by 27.1% during the fourth quarter. Boston Partners now owns 1,048,532 shares of the company’s stock valued at $46,034,000 after acquiring an additional 223,816 shares during the period. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of Enovis in a report on Wednesday, April 9th.

Enovis Stock Up 1.2 %

Shares of NYSE ENOV opened at $32.61 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -14.89 and a beta of 1.86. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $56.43. The firm’s 50-day simple moving average is $37.08 and its 200 day simple moving average is $42.06.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.